Brief: Painreform To Commence Second Part Of Phase 3 Clinical Trial To Evaluate PRF-110 Following Positive FDA Review of Drug Master File

PRF Technologies

11/09/2023 14:55

Sept 11 (Reuters) - PainReform Ltd  PRFX.O :
    * PAINREFORM ANNOUNCES PLANS TO COMMENCE SECOND PART OF
PHASE 3
CLINICAL TRIAL TO EVALUATE PRF-110 IN PATIENTS UNDERGOING
BUNIONECTOMY SURGERY FOLLOWING POSITIVE FDA REVIEW OF DRUG
MASTER FILE
    * PAINREFORM LTD - SECOND PART OF TRIAL IS EXPECTED TO
PROCEED IN
NEXT QUARTER OF 2023
    * PAINREFORM LTD - TARGETING TO COMMENCE SECOND PART OF
PHASE 3
CLINICAL TRIAL IN MID-Q4 2023

Source text for Eikon:  ID:nGNX6knTF9 
Further company coverage:  PRFX.O 

 ((reuters.briefs@thomsonreuters.com;))